Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
28,1 USD | +4,04 % | +48,76 % | +175,76 % |
29/04 | Cullinan Therapeutics nombra a Mary Kay Fenton directora financiera | MT |
16/04 | Transcript : Cullinan Oncology, Inc. - Special Call |
Resumen de negocios
Número de empleados: 85
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Nadim Ahmed
CEO | Chief Executive Officer | 56 | 18/10/21 |
Jeffrey Jones
CTO | Chief Tech/Sci/R&D Officer | 53 | 28/02/22 |
Jacquelyn Sumer
CMP | Compliance Officer | 46 | 15/08/22 |
Chief Tech/Sci/R&D Officer | 57 | 01/01/18 | |
Kevin Johnston
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/22 |
Chad Messer
IRC | Investor Relations Contact | - | 01/03/22 |
Corinne Savill
PRN | Corporate Officer/Principal | 64 | 01/02/17 |
Stephen Andre
HRO | Human Resources Officer | 62 | 01/04/22 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Chairman | 71 | 01/08/17 | |
Thomas Ebeling
BRD | Director/Board Member | 65 | 01/08/17 |
Stephen Webster
BRD | Director/Board Member | 63 | 01/09/20 |
Nadim Ahmed
CEO | Chief Executive Officer | 56 | 18/10/21 |
Director/Board Member | 52 | 28/02/22 | |
David Ryan
BRD | Director/Board Member | 57 | 01/11/22 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 43 065 645 | 40 310 790 ( 93,60 %) | 0 | 93,60 % |
Información de la empresa
Sector
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+175,76 % | 1163,2 M | |
+0,67 % | 42,19 mil M | |
+44,30 % | 40,15 mil M | |
-6,20 % | 28,31 mil M | |
+6,55 % | 24,63 mil M | |
-21,66 % | 18,2 mil M | |
+29,96 % | 12,01 mil M | |
-1,57 % | 11,76 mil M | |
+16,03 % | 10,4 mil M | |
-4,80 % | 9936,09 M |
- Bolsa de valores
- Acciones
- Acción CGEM
- Empresa Cullinan Therapeutics, Inc.